Nicotinamide riboside for treating progressive multiple sclerosis
Official title: Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study
Run by Haukeland University Hospital · NCT05740722 · Data updated 2026-11-12
This study is testing if a supplement called Nicotinamide riboside can help people with progressive multiple sclerosis slow down their disability over 30 months.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Haukeland University Hospital Academic / other |
| Locations | 1 site (Bergen) |
| Status | Recruiting |
| Started | May 3, 2023 |
| Main results expected | August 1, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | January 11, 2024 |
| Trial ID | NCT05740722 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with a diagnosis of progressive multiple sclerosis and documented evidence of disability progression.
✕Probably not a fit
Patients with relapsing forms of multiple sclerosis or those with certain comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and efficacy of Nicotinamide riboside (NR) in patients with progressive multiple sclerosis. Participants will be randomly assigned to receive either NR or a placebo for a duration of 30 months. The primary objective is to determine whether NR can delay disability progression in individuals diagnosed with progressive forms of MS. The study employs a double-blind design to ensure unbiased results.
Why it matters
Potential benefit: If successful, this treatment could slow down the progression of disability in patients with progressive multiple sclerosis.
How similar studies have gone: While the use of nicotinamide riboside is a novel approach in this context, similar studies targeting metabolic pathways in MS have shown promise.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria. * Aged 18-65 years. * EDSS 3-6.5 * Able to perform T25FW test * The participant must have documented evidence of disability progression observed during the 24 months before screening. * With or without a stable disease modifying therapy during the last three months. * Written informed consent for study participation. Exclusion Criteria: * A diagnosis of relapsing MS according to the revisions of the McDonald criteria * Neoplastic disease at baseline * Previous history of malignant melanoma or breast cancer * Stable phase of a progressive disease course * Pregnancy or lactating female patients * Dementia or other neurodegenerative disorder at baseline visit * Comorbidity (psychiatric or somatic) that precludes study participation * Use of high dose vitamin B3 supplementation within 30 days of enrolment * Genetically confirmed mitochondrial disease or metabolic disorder
Where it's running
-
Haukeland University Hospital
Bergen, Norway Recruiting
Study contacts
- Study coordinator: Kjell-Morten Myhr
- Email: kjell-morten.myhr@helse-bergen.no
- Phone: +47 55976031
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.